Nimbus Therapeutics Announces Closing of Gilead Sciences’ Acquisition of Nimbus Apollo, Inc., and its Acetyl-CoA Carboxylase (ACC) Inhibitor Program

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Nimbus Therapeutics, a biotechnology company focused on harnessing the
power of computational chemistry to design breakthrough drugs for
serious, underserved human diseases, today announced the recent closing
of Gilead Sciences, Inc.’s acquisition of Nimbus Apollo, Inc., a
wholly-owned subsidiary of Nimbus Therapeutics, and its Acetyl-CoA
Carboxylase (ACC) inhibitor program. The acquisition’s completion
triggered a $400 million upfront payment to Nimbus from Gilead. Per the
agreement between the two companies, Nimbus has the potential to receive
an additional $800 million in development-related milestones from Gilead
over time.
The Nimbus Apollo program includes the lead candidate NDI-010976, a
hepatotropic allosteric ACC inhibitor, and other preclinical ACC
inhibitors for the treatment of non-alcoholic steatohepatitis (NASH),
and for the potential treatment of hepatocellular carcinoma (HCC) and
other diseases. With the completion of the acquisition, Nimbus Apollo is
now a wholly-owned subsidiary of Gilead, and Gilead has assumed sole
responsibility for future development and commercialization of
NDI-010976 and other ACC inhibitors.
Nimbus continues to progress a diverse pipeline of therapeutic
candidates focused on serious unmet needs in oncology, immunology and
metabolic diseases. Placing a particular emphasis on the mechanistic
relationship between and among these primary therapeutic focus areas,
Nimbus is leveraging its unique computational chemistry approach to
advance novel molecules in cancer metabolism, immuno-oncology and
immuno-metabolism. The company’s pipeline addresses key biological
targets including Tyk2, KRas, and the recently unveiled addition of
non-nucleotide agonist and antagonist programs for STING (STimulator
of INterferon Genes)
as well as other undisclosed targets.
“We’re pleased to announce the completion of Gilead’s acquisition of
Nimbus Apollo, and we look forward to following the clinical progress of
NDI-010976,” said Don Nicholson, Ph.D., Chief Executive Officer at
Nimbus. “Our long-term vision at Nimbus is to build a robust
biotechnology company that is supportive of our mission to turn
difficult targets into medicines that matter. With our breakthrough
science, unmatched team and novel corporate structure, we are confident
that we can make significant contributions to human health.”
Nimbus is structured as a series of independent C corporations, each of
which houses distinct research and development programs focused on a
highly desirable, yet previously intractable disease target. This model
enables Nimbus to make investment and partnership decisions on an asset
versus pipeline basis, ensuring the full value of each program is
realized. It also affords Nimbus broad flexibility when determining
optimal clinical development plans, with the opportunity to advance
programs internally or consider a variety of partnering and
collaboration scenarios.
About Nimbus Therapeutics
Nimbus Therapeutics is a biotechnology company headquartered
in Cambridge, Massachusetts (USA). With its breakthrough computational
chemistry platform, enabled through its privileged partnership with
co-founder, Schrödinger, Inc., Nimbus is pioneering the application of
computational chemistry to design treatments for substantial and
underserved human diseases. The company’s focus on metabolic diseases,
cancer and immune-inflammatory disorders reflects the mechanistic
relationship between these disorders, and Nimbus’ ability to rapidly
tackle well validated targets as well as those that have proven
intractable to the approaches taken by others in the pharmaceutical and
biotechnology industry. Nimbus’ approach results in therapeutic
candidates with high potency, selectivity and other desirable drug-like
properties. To learn more, please visit www.nimbustx.com.